Printer Friendly Version View printer-friendly version
« Back
Seattle Genetics Initiates Phase II Clinical Trial with SGN-15 in Lung Cancer
August 21, 2001 at 12:00 AM EDT

Bothell, WA – August 21, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced the initiation of a phase II clinical trial for patients with non-small cell lung cancer with its product candidate, SGN-15, a monoclonal-antibody drug conjugate. The trial will evaluate SGN-15 in combination with the chemotherapeutic drug Taxotere®.

“This is the fourth potential indication for SGN-15, complementing our existing trials in breast, colon and prostate cancers,” stated H. Perry Fell, Ph.D., Chief Executive Officer at Seattle Genetics. “The broad range of cancers targeted by SGN-15 could provide us with large market opportunities.”

The study opened at two sites in Portland, OR, with additional sites to be added in the near future. The randomized trial comparing SGN-15 plus Taxotere® versus Taxotere® alone is expected to enroll up to 60 patients.

“Advanced lung cancer continues to be an area of significant unmet medical need,” commented Amy P. Sing, M.D., Senior Director of Medical and Regulatory Affairs at Seattle Genetics. “We are pleased to further our investigation of SGN-15 in lung cancer, the leading cause of cancer-related deaths among both men and women in the United States.” The American Cancer Society estimates that there will be nearly 160,000 deaths from lung cancer in 2001, accounting for 28 percent of all cancer deaths. Non-small cell is the most common, accounting for almost 80 percent of lung cancers, according to the American Cancer Society.

About Seattle Genetics

Seattle Genetics discovers and develops monoclonal antibody, or mAb, -based therapeutics to treat cancer and related diseases. The Company has four technologies: engineered mAbs, mAb-drug conjugates, single-chain immunotoxins and antibody-directed enzyme prodrug therapy (ADEPT). Seattle Genetics has built a diverse portfolio of drug candidates targeted to many types of human cancers, including two currently being tested in clinical trials. The Company also out-licenses its mAb-based technologies to strategic partners developing targeted therapies. Seattle Genetics has agreements with many organizations including Genentech, Medarex, Aventis, Bristol-Myers Squibb, Eos Biotechnology, Arizona State University, the University of Miami, and CLB Research and Development. More information about Seattle Genetics can be found at www.seattlegenetics.com.

Certain of the statements made in this press release are forward-looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks related to adverse clinical results as our product candidates move into and advance in clinical trials, risks inherent in early stage development and failure by Seattle Genetics to secure collaborators. More information about the risks and uncertainties faced by Seattle Genetics is contained in the Company's filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:
Peggy Pinkston, Manager of Investor Relations
(425) 527-4160
ppinkston@seagen.com